Skip to main content
Journal cover image

322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825)

Publication ,  Journal Article
Smith, MA; Maris, JM; Keir, ST; Friedman, HS; Lock, RB; Kolb, EA; Keshelava, N; Reynolds, CP; Morton, C; Houghton, PJ
Published in: European Journal of Cancer Supplements
November 2006

Duke Scholars

Published In

European Journal of Cancer Supplements

DOI

ISSN

1359-6349

Publication Date

November 2006

Volume

4

Issue

12

Start / End Page

101 / 101

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Smith, M. A., Maris, J. M., Keir, S. T., Friedman, H. S., Lock, R. B., Kolb, E. A., … Houghton, P. J. (2006). 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements, 4(12), 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5
Smith, M. A., J. M. Maris, S. T. Keir, H. S. Friedman, R. B. Lock, E. A. Kolb, N. Keshelava, C. P. Reynolds, C. Morton, and P. J. Houghton. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements 4, no. 12 (November 2006): 101–101. https://doi.org/10.1016/s1359-6349(06)70327-5.
Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, et al. 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements. 2006 Nov;4(12):101–101.
Smith, M. A., et al. “322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825).” European Journal of Cancer Supplements, vol. 4, no. 12, Elsevier BV, Nov. 2006, pp. 101–101. Crossref, doi:10.1016/s1359-6349(06)70327-5.
Smith MA, Maris JM, Keir ST, Friedman HS, Lock RB, Kolb EA, Keshelava N, Reynolds CP, Morton C, Houghton PJ. 322 POSTER Pediatric Preclinical Testing Program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825). European Journal of Cancer Supplements. Elsevier BV; 2006 Nov;4(12):101–101.
Journal cover image

Published In

European Journal of Cancer Supplements

DOI

ISSN

1359-6349

Publication Date

November 2006

Volume

4

Issue

12

Start / End Page

101 / 101

Publisher

Elsevier BV

Related Subject Headings

  • Oncology & Carcinogenesis